Endobronchial Ultrasound Biopsy Market: as GLOBOCAN’s 2.48 million annual global lung cancer cases sustain structural demand for minimally invasive mediastinal staging, incremental bronchoscope and ultrasound platform generations from Olympus and FUJIFILM compound diagnostic precision gains onto an already-established clinical workflow rather than requiring pulmonologists to adopt a new technique, so device generation upgrades convert almost directly into replacement procurement, and direct distribution expansion into underserved regional markets becomes as important a growth lever as the underlying technology itself.

The global endobronchial ultrasound biopsy market size was USD 812.4 Million in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as sustained global lung cancer incidence maintaining structural demand for mediastinal staging, successive bronchoscope and ultrasound processor generations from Olympus and FUJIFILM advancing diagnostic precision within an already-established clinical workflow, and direct distribution expansion into underserved Latin American and other regional markets. The first driving factor is the sustained scale of global lung cancer incidence, which drives structural, recurring demand for endobronchial ultrasound-guided transbronchial needle aspiration as the standard minimally invasive mediastinal staging technique. GLOBOCAN 2022 data documented 2.48 million global lung cancer cases, and accurate mediastinal lymph node staging is a required step in determining appropriate treatment pathway for the substantial share of these cases involving suspected nodal involvement, sustaining recurring EBUS-TBNA procedure demand tied directly to lung cancer diagnosis volume. The second driving factor is successive generations of EBUS bronchoscope and compatible ultrasound processor technology that compound incremental diagnostic precision improvements onto an already-established clinical procedure rather than requiring pulmonologists to adopt an entirely new technique. Olympus Corporation’s third-generation BF-UC290F bronchoscope and its compatibility with FUJIFILM’s ARIETTA 750 FF ENDO ultrasound processor are advancing EBUS-TBNA diagnostic precision through incremental image quality and needle guidance improvements built on the same core procedural workflow pulmonologists already use. The third driving factor is direct distribution expansion by leading device manufacturers into underserved regional markets, converting previously indirect or distributor-mediated market access into direct commercial presence. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way an incremental bronchoscope generation upgrade widens its own revenue base as hospitals with an already-established EBUS-TBNA programme replace their existing platform with the newest generation, letting each successive device generation capture near-automatic replacement procurement from a hospital that has already committed to the underlying clinical procedure rather than requiring a new adoption decision. Once a hospital pulmonology department has established an EBUS-TBNA programme with staff trained on the technique, upgrading to a newer-generation bronchoscope from the same or a compatible ultrasound processor manufacturer is a straightforward replacement decision rather than a new procedure adoption decision, so the value of an established EBUS-TBNA programme compounds across successive device generation upgrades. As a result, demand and revenue share are concentrating around the established EBUS-TBNA platform vendors, Olympus and FUJIFILM, whose successive device generations capture near-automatic replacement procurement from hospitals with existing programmes, and the forecast tilts toward incremental generation upgrades within established vendor relationships rather than new-vendor displacement. For instance, in January 2025, Olympus Latin America closed the acquisition of the distribution business of Sur Medical SpA in Chile, establishing a new direct subsidiary, Olympus Corporation Chile, to sell and distribute its full medical technology portfolio, including EBUS bronchoscope systems, directly rather than through the third-party distributor that had represented Olympus in Chile since 2013. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the sustained global scale of lung cancer incidence, which drives recurring, structural demand for mediastinal staging as a required diagnostic step. Accurate mediastinal lymph node staging directly determines appropriate treatment pathway selection for lung cancer patients with suspected nodal involvement, and EBUS-TBNA has become the standard minimally invasive technique for this staging step precisely because it avoids the greater invasiveness of surgical mediastinoscopy, so lung cancer incidence and EBUS-TBNA procedure volume are directly and structurally linked. GLOBOCAN 2022 data documented 2.48 million global lung cancer cases, establishing the scale of the underlying diagnostic demand base that sustains recurring EBUS-TBNA procedure volume across hospital pulmonology departments and cancer centres globally. The effect on the market is that EBUS-TBNA procedure volume growth tracks lung cancer diagnosis volume growth directly, providing a demand floor for the market that is largely independent of any single technology or reimbursement development. These are some of the key factors driving revenue growth of the market.

The second driver is the pattern of successive bronchoscope and ultrasound processor generations that improve diagnostic precision without requiring pulmonologists to adopt a fundamentally new procedural technique. A hospital with an established EBUS-TBNA programme and trained staff can upgrade to a newer device generation as a straightforward equipment replacement decision, and this is fundamentally different from a new technology adoption decision requiring new staff training and clinical workflow redesign, so incremental generation improvement and near-automatic replacement procurement are directly linked in a way that would not hold for a genuinely novel diagnostic technique. Olympus Corporation’s third-generation BF-UC290F bronchoscope and its compatibility with FUJIFILM’s ARIETTA 750 FF ENDO ultrasound processor are advancing EBUS-TBNA diagnostic precision through incremental image quality and needle guidance improvements built on the same core procedural workflow pulmonologists already use. The effect on the market is that device generation upgrade cycles function as a predictable, recurring revenue driver for established EBUS platform vendors, distinct from and additive to underlying procedure volume growth. These are some of the key factors driving revenue growth of the market.

“Olympus Latin America’s January 2025 acquisition of Sur Medical’s Chilean distribution business, establishing the new direct subsidiary Olympus Corporation Chile, illustrates how leading EBUS device manufacturers are converting distributor-mediated regional market access into direct commercial presence as a distinct growth lever alongside device generation innovation.”

The third driver is direct distribution expansion by leading manufacturers into markets previously served through third-party distributor relationships. Direct distribution typically enables faster product introduction, more consistent clinical training support, and closer customer relationship management than a third-party distributor arrangement, and this improvement in market access execution can accelerate adoption in a region independent of any underlying change in the technology itself, so distribution model change and regional market penetration acceleration are directly linked. Olympus Latin America closed the acquisition of the distribution business of Sur Medical SpA in Chile in January 2025, establishing a new direct subsidiary, Olympus Corporation Chile, to sell and distribute its full medical technology portfolio directly rather than through the third-party distributor that had represented Olympus in Chile since 2013. The effect on the market is that direct distribution investment is becoming a genuine competitive lever in regional markets, not merely a logistics and operational decision, as manufacturers seek to accelerate adoption in underserved geographies. These are some of the key factors driving revenue growth of the market.

However, the endobronchial ultrasound biopsy market faces adoption constraints from the significant capital cost of EBUS bronchoscope and ultrasound processor systems, the specialised interventional pulmonology training required to perform EBUS-TBNA procedures competently, and reimbursement and procedure volume concentration at larger academic and cancer centres. Because EBUS bronchoscope and compatible ultrasound processor systems represent a substantial capital equipment investment, often requiring a dedicated bronchoscopy suite and supporting infrastructure, smaller hospitals and those in lower-resource healthcare systems often lack the procedure volume to justify the investment relative to referring patients to a specialist centre with an already-established EBUS-TBNA programme. Specialised training requirements are a second constraint, because competent EBUS-TBNA performance requires dedicated interventional pulmonology fellowship training beyond general pulmonology or diagnostic bronchoscopy training, and this training pathway produces a limited annual supply of adequately trained interventional pulmonologists relative to the total addressable hospital base that might otherwise wish to establish an EBUS-TBNA programme. Reimbursement and procedure volume concentration is the third constraint, since EBUS-TBNA procedure reimbursement structures and referral patterns in many healthcare systems tend to concentrate diagnostic volume at larger cancer centres and academic medical centres that can demonstrate sufficient procedure volume and outcomes data, limiting broader community hospital adoption regardless of whether the equipment cost barrier alone could otherwise be overcome. These factors substantially limit endobronchial ultrasound biopsy market growth over the forecast period.

Based on product type, the global endobronchial ultrasound biopsy market is segmented into EBUS bronchoscopes, EBUS-TBNA needles, and ultrasound processors and imaging systems. EBUS bronchoscopes hold the largest revenue share, because they represent the highest-value capital equipment component and the item most directly associated with successive Olympus and FUJIFILM device generation upgrades, which suits the market’s concentration among these two established vendors. EBUS-TBNA needles remain established as a high-frequency, recurring single-use consumable purchase across every procedure regardless of bronchoscope generation, generating steady replacement revenue, but they cannot match the capital equipment value of bronchoscope and processor systems. Ultrasound processors and imaging systems are expected to register rapid revenue growth in the global endobronchial ultrasound biopsy market over the forecast period, driven by compatibility upgrades such as FUJIFILM’s ARIETTA 750 FF ENDO, which is why processor-bronchoscope compatibility has become a key competitive consideration.

Mediastinal lymph node staging application is expected to account for the largest revenue share in the global endobronchial ultrasound biopsy market during the forecast period

Based on application, the global endobronchial ultrasound biopsy market is segmented into mediastinal lymph node staging and peripheral pulmonary lesion diagnosis applications. Mediastinal lymph node staging holds the largest revenue share, because it represents the original and most established EBUS-TBNA clinical application directly tied to lung cancer staging protocols, which suits the market’s core demand driver in GLOBOCAN-documented lung cancer incidence. Peripheral pulmonary lesion diagnosis is expected to register rapid revenue growth in the global endobronchial ultrasound biopsy market over the forecast period, driven by expanding radial EBUS applications for smaller, more peripherally located lung nodules increasingly detected through low-dose CT lung cancer screening programmes.

Based on end-use, the global endobronchial ultrasound biopsy market is segmented into hospital pulmonology departments, cancer centres and oncology institutes, and ambulatory bronchoscopy suites. Hospital pulmonology departments hold the largest revenue share, reflecting their position as the primary setting for established EBUS-TBNA programmes with the procedure volume and trained interventional pulmonology staff to sustain ongoing device generation upgrades. Cancer centres and oncology institutes represent a significant and steadily growing end-use category given their concentrated lung cancer patient population, while ambulatory bronchoscopy suites remain a smaller but emerging setting as the procedure gradually extends beyond traditional hospital-based pulmonology departments.

Based on regional analysis, the endobronchial ultrasound biopsy market in North America accounted for largest revenue share in 2025. The United States leads because it has the largest concentration of academic medical centres and cancer centres with established interventional pulmonology fellowship training programmes and EBUS-TBNA procedure volume. Olympus and FUJIFILM, the leading global EBUS device manufacturers, concentrate significant commercial and product development activity in the United States given its scale of lung cancer diagnosis and treatment infrastructure. The concentration of interventional pulmonology training infrastructure and procedure volume in the United States also means new EBUS device generations are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national endobronchial ultrasound biopsy markets within Europe. The region’s well-established academic pulmonology infrastructure and CE-marking regulatory pathway sustain steady demand, and Olympus maintains a strong European commercial presence. The result is steady rather than rapid growth, shaped more by the region’s already-mature interventional pulmonology infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national endobronchial ultrasound biopsy markets within the region. Japan is home to Olympus and FUJIFILM, anchoring significant regional commercial and product development activity, while China’s rapidly rising lung cancer incidence and expanding interventional pulmonology training capacity are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate-to-rapid revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endobronchial ultrasound biopsy markets within the region, with Chile representing a smaller but strategically significant market following Olympus’s January 2025 direct distribution establishment. The indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised bronchoscope and ultrasound processor systems that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main cancer centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial endobronchial ultrasound biopsy markets within the GCC. The UAE is the most established endobronchial ultrasound biopsy market on the continent given its concentrated private hospital and cancer centre infrastructure, while the wider Gulf states and broader African markets are still building interventional pulmonology training and equipment infrastructure from scratch.